Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Pfizer is looking to strengthen its grip on mRNA research and development with a $470 million new facility, and Eikon is planning to open a 25,000 facility. Both will be based in New York.
Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week’s Movers & Shakers.
Researchers at MD Anderson Cancer Center have uncovered a new method in which some solid tumor cells are evading detection: the formation of their own type of collagen.
Freeline Therapeutics’ hemophilia B drug demonstrated the strong possibility that a single injection of FLT180a, an experimental gene therapy, can reduce or eliminate the need for weekly injections.
Assembly Biosciences and X4 Pharmaceuticals have announced significant layoffs and reprioritization endeavors to let go of underperforming initiatives.
Frontera Therapeutics closed on a Series B funding round worth $160 million and announced an IND approval by the FDA for rare genetic retinal disease
The whistleblower claim was brought by former employee Michael Bawduniak, who accused the company of paying off doctors to favor its multiple sclerosis drugs over those of its competitors.
Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.
According to a study, people with certain gut disorders may be at greater risk of Alzheimer’s disease, and researchers have discovered a potential use for ASOs against cystic fibrosis.
As Severin Schwan prepares to step aside from the day-to-day leadership of Roche, Thomas Schinecker is waiting in the wings to assume the company’s top leadership spot.
A new study published in Frontiers in Aging Neuroscience by researchers at Tufts University further supports the theory that there’s a link between gum disease and Alzheimer’s.
Vertex and Verve announced they had entered an exclusive four-year research partnership to discover and nurture a gene editing therapy for yet-undisclosed liver disease.
